Last reviewed · How we verify
Ganoderma lucidum — Competitive Intelligence Brief
marketed
Herbal/botanical immunomodulator
Oncology, Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Ganoderma lucidum (Ganoderma lucidum) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Ganoderma lucidum (reishi mushroom) modulates immune function and promotes apoptosis through polysaccharide and triterpene constituents that enhance natural killer cell activity and reduce inflammatory cytokines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ganoderma lucidum TARGET | Ganoderma lucidum | Second Affiliated Hospital, School of Medicine, Zhejiang University | marketed | Herbal/botanical immunomodulator |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Herbal/botanical immunomodulator class)
- Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ganoderma lucidum CI watch — RSS
- Ganoderma lucidum CI watch — Atom
- Ganoderma lucidum CI watch — JSON
- Ganoderma lucidum alone — RSS
- Whole Herbal/botanical immunomodulator class — RSS
Cite this brief
Drug Landscape (2026). Ganoderma lucidum — Competitive Intelligence Brief. https://druglandscape.com/ci/ganoderma-lucidum. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab